The Pharma 5: Washington knocks out wobbly D2C exception to worthy Learned Intermediary
This month, Jackie Karama, an associate in Los Angeles whose practice focuses on pharma disputes, discusses:
- Securities – clinical trials
- Consumer sales – standing
- FDA - NDA regulation
- Orphan Drug Act – exclusivity
- Learned Intermediary – D2C